Neutropenia – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides data on the neutropenia clinical trial scenario. This report provides top-line data relating to the clinical trials on Neutropenia. The report includes an overview of trials count and their average enrolment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
Neutropenia clinical trial report consists of 555 trials. Trials conducted by companies in Phase IV, Phase III, Phase II and Phase I stand at 59, 52, 60 and 91 respectively. Similarly, the trials with different status compile of Completed – 367, Ongoing – 88, Planned – 27, Suspended – 1, Terminated – 39 and Withdrawn – 33. Out of 367 completed trials 202 trials have achieved endpoints.
What are the market dynamics of the global neutropenia therapeutics clinical trials sector?
The number of neutropenia clinical trials conducted globally were constant for the period 2016-2020. The average number of patients enrolled was highest in the year 2019. As of November 2021, the majority of trials have been sponsored by institutions followed by companies and government. Out of 367 completed trials, 234 trials have results and 202 of trials reached endpoints. There were 88 clinical trials in progress and 367 trials were completed. The trials that were terminated/suspended or withdrawn accounted to 73. This was due to the lack of efficacy, safety, and lack of accrual of subjects. There were 88 clinical trials in progress of which 33% (29 trials) were in Phase IV study. There were 181 clinical trials in Phase II, of which 28 clinical trials were in progress for the time period 1995-2021.
What are the top regions and countries in the global neutropenia therapeutics clinical trials sector?
In total there were 555 clinical trials conducted on neutropenia, as of November 2021, of these 209 clinical trials were in Asia-Pacific. More than 35% of the clinical trials were conducted in Asia-Pacific.
Asia-Pacific: As of November 2021, in the Asia-Pacific region, China has the highest number of neutropenia clinical trials followed by Japan, India, Australia, and South Korea.
Europe: Among the European countries, Germany has the highest number of neutropenia clinical trials, as of November 2021, followed by Russia, France, Hungary, and Italy.
North America: In the country-wise analysis, the US has the highest number of neutropenia clinical trials in North America followed by Canada and Mexico.
Middle East and Africa: Iran has the highest number of neutropenia clinical trials in the Middle East & Africa followed by Israel, Egypt, Botswana, and the UAE.
Central and South America: Brazil has the highest number of neutropenia clinical trials in the region followed by Chile, Colombia, Peru, and Argentina.
G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of neutropenia to hematological disorders clinical trials. In total there were 312 clinical trials conducted on Neutropenia, as of November 2021 in G7 Countries, of these 152 clinical trials were in the US. There were 40 clinical trials in progress and 193 trials are completed. The trials that are terminated/suspended or withdrawn accounted to 38.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico has the highest proportion of neutropenia to hematological disorders clinical trials as of November 2021. In total there were 160 clinical trials conducted on Neutropenia, in E7 Countries, of these 78 clinical trials were in China. There were 28 clinical trials in progress and 87 trials were completed. The trials that were terminated/suspended or withdrawn accounted to 24. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
Global neutropenia therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global neutropenia therapeutics clinical trials sector?
As of November 2021, CSPC Pharmaceutical Group Ltd and Merck & Co Inc sponsored the highest number of neutropenia clinical trials. Other major companies in the sector are Amgen Inc, Pfizer Inc, Evive Biotech, Teva Pharmaceutical Industries Ltd, Apotex Pharmaceutical Holdings Inc, Novartis AG, Kirin Holdings Co Ltd, and Intas Pharmaceuticals Ltd.
Global neutropenia therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, China, Japan, Germany, India, Canada, Russia, France, Australia, and Hungary |
Key companies | CSPC Pharmaceutical Group Ltd, Merck & Co Inc, Amgen Inc, Pfizer Inc, Evive Biotech, Teva Pharmaceutical Industries Ltd, Apotex Pharmaceutical Holdings Inc, Novartis AG, Kirin Holdings Co Ltd, and Intas Pharmaceuticals Ltd. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for un-accomplishment.
- The report provides enrollment trends for the past five years.
- Report provides latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrolment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Merck & Co Inc
Amgen Inc
Pfizer Inc
Evive Biotech
Teva Pharmaceutical Industries Ltd
Apotex Pharmaceutical Holdings Inc
Novartis AG
Kirin Holdings Co Ltd
Intas Pharmaceuticals Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global neutropenia therapeutics clinical trials sector?
The key countries in the global neutropenia therapeutics clinical trials sector are the US, China, Japan, Germany, India, Canada, Russia, France, Australia, and Hungary.
-
Which are the key companies in the global neutropenia therapeutics clinical trials sector?
The key companies in the global neutropenia therapeutics clinical trials sector are CSPC Pharmaceutical Group Ltd, Merck & Co Inc, Amgen Inc, Pfizer Inc, Evive Biotech, Teva Pharmaceutical Industries Ltd, Apotex Pharmaceutical Holdings Inc, Novartis AG, Kirin Holdings Co Ltd, and Intas Pharmaceuticals Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.